Brochure
More information from http://www.researchandmarkets.com/reports/2365661/
Renal Cell Carcinoma (Event Driven)
Description: The Renal Cell Carcinoma market is highly lucrative. We anticipate that Pfizer’s axitinib—which has been filed for regulatory approval in 2011 in Europe and the United States—Aveo Pharmaceuticals/Astellas
Pharma/Kyowa Hakko Kirin’s tivozanib, and Novartis’s dovitinib will launch in this indication during our 2010-2020 forecast period and will further bolster the market. However, a large unmet need to improve the prognosis of RCC patients remains.
Contents: Executive Summary
What are the key parameters of the RCC market? What factors are driving the market for RCC therapies? What factors are constraining the market for RCC therapies? What are the drug development activities of note in RCC? What do the experts say?
What key challenges and opportunities remain? 1 . Etiology and Pathophysiology
Overview
Disease Pathophysiology Risk Factors
Genetic and Hereditary Factors Other Risk Factors
Cellular Classification
Clear-Cell Renal Cell Carcinoma Papillary Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma Collecting-Duct Carcinoma
Unclassified Renal Cell Carcinoma Molecular Markers
Staging Symptoms Prognosis
Spread of Renal Cell Carcinoma Recurrence
Pathways and Drug Targets
2 . Epidemiology and Patient Populations Overview
Disease Definition Methods
Newly Diagnosed Incident Cases Recurrent Incident Cases Staging
Diagnosed and Drug-Treated Populations Percentage Diagnosed
Percentage Drug-Treated
Stage IV, First-Line Drug-Treatable Population Stage IV, Second-Line Drug-Treatable Population Stage IV, Third-Line Drug-Treatable Population 3 . Current Therapies and Medical Practice Overview
Renal Cell Carcinoma Diagnosis
Treatment Guidelines Clinical Trial End Points
Drug Treatment
Commonly Prescribed Drugs Regimen Dosing
Clinical Analysis of Therapies Used as First-Line Treatment for Advanced Renal Cell Carcinoma
Clinical Analysis of Therapies Used as Second-Line Treatment for Advanced Renal Cell Carcinoma
Clinical Analysis of Therapies Used as Third-Line Treatment for Advanced Renal Cell Carcinoma
Clinical Development Treatment Algorithm
Country-Specific Medical Practice Reimbursement
4 . Unmet Needs . . . . Overview
Improved Survival for Advanced RCC Patients
Adjuvant Therapy for Patients with Localized Disease at Intermediate and High Risk of Relapse
Optimized Treatment by Line of Therapy Biomarkers to Aid in Diagnosis and Treatment Agents for Non-Clear-Cell RCC
Improved Quality of Life with Advanced RCC Combination Use of RCC Agents
5 . Emerging Therapies Overview
Future Positioning of Key Competitors Drug Development and Regulatory Hurdles Angiogenesis Inhibitors
Overview
Mechanism of Action Axitinib
Tivozanib Dovitinib Ramucirumab Foretinib
Immunotherapies Overview
Mechanism of Action Girentuximab
Naptumomab Estafenatox IMA-901
AGS-003 Vitespen
Renal Cell Carcinoma 6 . Market Outlook Overview
Drug-Class-Specific Trends Angiogenesis Inhibitors
Mammalian Target of Rapamycin (mTOR) Inhibitors Cytokines
Segment-Specific Trends Stage IV First-Line Setting Stage IV Second-Line Setting Stage IV Third-Line Setting Alternative Market Scenarios
Appendix A . Bibliography—Renal Cell Carcinoma Appendix B . Market Forecast Methodology Bottom-Up Market Forecasting Overview
Patient Populations Drug-Specific Assumptions Drug-Specific Assumptions General Sources of Data
Pricing, Dosing, Days of Therapy, and Compliance Assumptions General Statements About Pricing
Dosing, Cycles and Compliance Generic Erosion
Emerging Therapy Prices
Appendix C . Experts Interviewed—Renal Cell Carcinoma Tables and Figures
Renal Cell Carcinoma
Table 1-1 . Lifestyle Factors Linked to the Development of Renal Cell Carcinoma Table 1-2 . Select Genes Reportedly Involved in Renal Cell Carcinoma
Table 1-3. Definitions of the TNM Staging System for Renal Cell Carcinoma Table 1-4 . TNM Staging System for Renal Cell Carcinoma
Table 1-5 . UCLA Integrated Staging System Renal Cell Carcinoma Risk Groups
Table 1-6 . The Memorial Sloan-Kettering Cancer Center Risk Assessment System for Stage IV Renal Cell Carcinoma Patients
Table 2-1 . Number of Diagnosed Incident Cases of Renal Cell Carcinoma in the Major Pharmaceutical Markets by Stage at Diagnosis, 2010-2020
Table 2-2 . Drug-Treatable Renal Cell Carcinoma Populations, by Stage, 2010-2020 Table 2-3 . Key Sources for Renal Cell Carcinoma Epidemiology and Patient Flow Model
Table 3-1 . Treatment Providers and Diagnostic Patterns in the Major Markets for Renal Cell Carcinoma Table 3-2 . Renal Cell Carcinoma Treatment Guidelines, by Market
Table 3-3 . Key End Points Used in Clinical Trials for Renal Cell Carcinoma
Table 3-4 . Current Therapies Used for Renal Cell Carcinoma—Mechanism of Action Table 3-5 . Key Therapeutic Approaches to Treatment of Stage IV Renal Cell Carcinoma Table 3-6 . Brand and Manufacturer of Current Therapies to Treat Renal Cell Carcinoma Table 3-7 . Current Drug and Regimen Dosing for Renal Cell Carcinoma
Table 3-8 . Expert Insight: Sunitinib vs . Pazopanib
Table 3-9. Efficacy Achievements for Renal Cell Carcinoma in First-Line Therapy
Table 3-10 . Most Frequent Toxicities Encountered During First-Line Treatment of Renal Cell Carcinoma Table 3-11. Efficacy Achievements in Second- and Subsequent-Line Treatment of Renal Cell Carcinoma Table 3-12 . Most Frequent Toxicities Encountered During Second- and Subsequent-Line Treatment of Renal Cell Carcinoma
Table 3-13 . Select Trials Investigating Therapies in the Treatment of Renal Cell Carcinoma Table 3-14 . Expert Insight: Therapies Used to Treat Renal Cell Carcinoma
Table 3-15 . Reimbursement Environment for Renal Cell Carcinoma, by Market Table 5-1 . Emerging Therapies in Development for Renal Cell Carcinoma
Table 5-2 . Estimated Launch Dates of Key Emerging Therapies for the Treatment of Renal Cell Carcinoma Table 5-3 . Main Targets of Current and Emerging Renal Cell Carcinoma Angiogenesis Inhibitors
Table 6-1 . Sales of Drugs to Treat Renal Cell Carcinoma (All Populations) in the Major Renal Cell Carcinoma Pharmaceutical Markets, 2010-2020
Table 6-2 . Timeline of Key Market Events for Renal Cell Carcinoma
Table 6-3 . Alternative Scenarios for the Renal Cell Carcinoma Market Through 2020 Table B-1 . Sources for Drug Prices
Table B-2 . Current Drug and Regimen Dosing for Renal Cell Carcinoma Figure 1-1 . The Kidney
Figure 1-2 . The VHL Pathway—Drug Targets for Renal Cell Carcinoma .
Figure 1-3 . Five-Year Survival Rate as Determined by AJCC Disease Stage for Renal Cell Carcinoma
Figure 2-1 . Crude Incidence of Renal Cell Carcinoma in the Major Pharmaceutical Markets, by Gender, 2009 Figure 3-1 . Treatment Algorithm for Renal Cell Carcinoma
Figure 4-1 . Unmet Needs: Attainment and Remaining Opportunity in Renal Cell Carcinoma Figure 6-1 . Renal Cell Carcinoma Therapies, 2010-2020, Market Share
Figure 6-2 . Renal Cell Carcinoma Therapy Sales by Region, 2010-2020 Figure 6-3 . Renal Cell Carcinoma Therapy Sales, by Line, 2010-202 Figure 6-4 . Timeline of Near-Term Events in Renal Cell Carcinoma
Figure 6-5 . Sales of Major Drugs in the Renal Cell Carcinoma First-Line Market, 2010-2020 Figure 6-6 . Sales of Major Drugs in the Renal Cell Carcinoma Second-Line Market, 2010-2020
Figure 6-7 . Sales of Major Drugs in the Renal Cell Carcinoma Third-Line Market, 2010-2020
Ordering: Order Online - http://www.researchandmarkets.com/reports/2365661/
Order by Fax - using the form below
Order by Post - print the order form below and send to Research and Markets,
Guinness Centre, Taylors Lane, Dublin 8, Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct.
Product Format
Please select the product format and quantity you require:
Contact Information
Please enter all the information below in BLOCK CAPITALS
Product Name: Renal Cell Carcinoma (Event Driven)
Web Address: http://www.researchandmarkets.com/reports/2365661/
Office Code: SC
Quantity
Electronic (PDF)
-Single User: USD 15000
Title: Mr Mrs Dr Miss Ms Prof
First Name: Last Name:
Email Address: * Job Title: Organisation: Address: City:
Postal / Zip Code: Country:
Phone Number: Fax Number:
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World
Pay by credit card: You will receive an email with a link to a secure webpage to enter yourcredit card details.
Pay by check: Please post the check, accompanied by this form, to: Research and Markets,
Guinness Center, Taylors Lane, Dublin 8, Ireland.
Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083 Bank Address Ulster Bank,
27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
